Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

Clinical Therapeutics
David Russell-JonesJan Bolinder

Abstract

The purpose of this trial was to compare the effects of QD basal insulin replacement using insulin detemir versus neutral protamine Hagedorn (NPH) insulin in basal-bolus therapy in combination with regular human insulin (HI) in patients with type 1 diabetes mellitus (DM). This was a 6-month, prospective, randomized, open-label, controlled, parallel-group trial conducted at 92 sites in Europe and Australia. The trial population included men and women with type 1 DM for at least 1 year aged > or = 18 years with glycosylated hemoglobin (HbA(1c)) <== 12% already taking QD basal-bolus treatment with an intermediate- or long-acting insulin and a fast-acting human insulin or insulin analogue as bolus insulin. Patients were randomly assigned (2:1) to 6 months of treatment with insulin detemir or NPH at bedtime in combination with HI with main meals. Main outcome measures were blood glucose control as assessed by HbA(1c), fasting plasma glucose (FPG), 9-point self-monitored blood glucose (SMBG) profiles, 24-hour continuous blood glucose profiles, hypoglycemia, weight gain, and adverse events. Of the 749 patients randomized to treatment, 747 were exposed to trial products and included in the intent-to-treat analysis set. Seven hundred pa...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Sep 12, 2001·Lancet·D R OwensG B Bolli

❮ Previous
Next ❯

Citations

Mar 5, 2009·Advances in Therapy·Jean-Louis Selam, Luigi F Meneghini
Apr 17, 2010·Primary Care Diabetes·Luigi MeneghiniMartin J Abrahamson
Nov 9, 2006·Proceedings of the National Academy of Sciences of the United States of America·Bart KeymeulenDaniel Pipeleers
Aug 22, 2008·Diabetes Technology & Therapeutics·Melanie J DaviesPer Clauson
May 18, 2010·Diabetes Technology & Therapeutics·Alan C Moses, Christoph Koenen
Jun 28, 2011·Diabetes Technology & Therapeutics·Stuart LittlePhilip Home
Mar 3, 2007·Southern Medical Journal·Luigi Meneghini
Mar 30, 2007·Diabetes, Obesity & Metabolism·K Hermansen, M Davies
Oct 11, 2007·Diabetes, Obesity & Metabolism·David Russell-Jones, Rehman Khan
Mar 10, 2009·Diabetes, Obesity & Metabolism·M MonamiE Mannucci
Jan 6, 2009·Diabetes, Obesity & Metabolism·B SheldonJ Wright
Jul 2, 2010·Diabetes, Obesity & Metabolism·A R SørensenC L Brand
Mar 31, 2007·International Journal of Clinical Practice·J Tibaldi, R E Rakel
Feb 18, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Sumeet R SinghHeather Bennett
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Gregory E Peterson
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Jean-Pierre Le Floch
Mar 1, 2007·Vascular Health and Risk Management·Jean-Christophe Philips, André Scheen
Jul 11, 2009·Vascular Health and Risk Management·Yared N DemssieHandrean Soran
Jan 1, 2010·Clinical Medicine Insights. Endocrinology and Diabetes·Jason R Young, Carrie McAdam-Marx
Mar 21, 2007·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Brigitte L Sicat, Laura A Morgan
Oct 4, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Dong-Churl Suh, Mark Aagren

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.